Diagnostic biomarkers for fibrotic lung disease have not been validated; however, increased circulating fibrocytes have been suggested in patients with IPF, though data regarding vascular endothelial growth factor are contradictory. Asthma is not associated with disease progression.
Functional parameters used to monitor and evaluate disease progression include the percentage value on the predicted forced vital capacity, the diffusion capacity of the lung for carbon monoxide, and 6-minute walk distance data. Worsening dyspnea is also a primary indicator of disease progression, as are acute exacerbations.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Skill Checkup: A 59-Year-Old Man With Dyspnea on Exertion and a Nonproductive Cough - Medscape - Apr 15, 2022.